Department of Psychology, Texas Institute for Measurement, Evaluation and Statistics (TIMES), University of Houston, Health and Biomedical Sciences Building 1, 4849 Calhoun Road, Houston, TX, 77204-6022, USA.
Molecular VIrology and Microbiology Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
Psychopharmacology (Berl). 2021 Jan;238(1):281-292. doi: 10.1007/s00213-020-05681-y. Epub 2020 Oct 23.
Methamphetamine is a highly abused psychostimulant drug and its use remains a major public health concern worldwide with limited effective treatment options. Accumulative evidence reveals the influence of gut microbiota on the brain, behavior, and health as a part of the gut-brain axis but its involvement in modulating this substance use disorder remains poorly understood.
We sought to determine whether methamphetamine exposure and cessation or withdrawal alter the intestinal gut microbiota as well as characterize cessation-induced behavioral changes.
Male, Sprague-Dawley rats were administered methamphetamine (2 mg/kg; s.c.) or vehicle (n = 8 per group) twice per day for 14 consecutive days. On various days before, during, and after administration, fecal samples were collected and tests of anxiety- and depressive-like behaviors were conducted.
Methamphetamine administration and cessation did not alter the relative abundance of bacteria but significantly changed the composition of gut bacteria through 16S rRNA sequencing. These changes were normalized after 7 days of methamphetamine cessation. Moreover, acute methamphetamine cessation induced depressive-like behavior, with an increase in immobility in the forced swim test but did not alter anxiety-like behaviors in tests of open field test or elevated plus maze.
These findings provide direct evidence that methamphetamine and its cessation cause gut dysbiosis and that the latter associates with depressive-like behavior in rodents. Our observation will contribute to a better understanding of the function of gut microbiota in the process of substance use disorders and guide the choice of target therapeutics.
甲基苯丙胺是一种高度滥用的精神兴奋剂药物,其使用仍然是全球范围内的主要公共卫生关注点,而有效的治疗选择有限。累积的证据表明,肠道微生物群作为肠脑轴的一部分,对大脑、行为和健康有影响,但它在调节这种物质使用障碍方面的作用仍知之甚少。
我们试图确定甲基苯丙胺暴露和戒断或戒断是否会改变肠道肠道微生物群,并描述戒断引起的行为变化。
雄性 Sprague-Dawley 大鼠每天两次接受甲基苯丙胺(2mg/kg;sc)或载体(每组 8 只)连续 14 天。在给药前、期间和之后的不同日子里,收集粪便样本并进行焦虑和抑郁样行为测试。
甲基苯丙胺的给予和戒断并没有改变细菌的相对丰度,但通过 16S rRNA 测序显著改变了肠道细菌的组成。这些变化在甲基苯丙胺戒断 7 天后恢复正常。此外,急性甲基苯丙胺戒断诱导抑郁样行为,强迫游泳试验中不动时间增加,但在旷场试验或高架十字迷宫试验中不改变焦虑样行为。
这些发现提供了直接证据,表明甲基苯丙胺及其戒断会导致肠道菌群失调,而后者与啮齿动物的抑郁样行为有关。我们的观察结果将有助于更好地理解肠道微生物群在物质使用障碍过程中的功能,并指导选择靶向治疗药物。